AP129A - Expression of retrovirus gag protein eukaryotic cells - Google Patents

Expression of retrovirus gag protein eukaryotic cells Download PDF

Info

Publication number: AP129A
Authority: AP; ARIPO
Prior art keywords: cells; gag; precursor protein; recombinant; dna molecule
Prior art date: 1988-06-03

Application number

APAP/P/1989/000126A

Other languages

English (en)

Other versions

AP8900126A0 (en

Inventor

Eric Jacobs

Dirk Gheysen

Original Assignee

Smithkline Biologicals S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-06-03

Filing date

1989-05-22

Publication date

1991-04-17

1989-05-22 Application filed by Smithkline Biologicals S A filed Critical Smithkline Biologicals S A

1989-07-31 Publication of AP8900126A0 publication Critical patent/AP8900126A0/xx

1991-04-17 Application granted granted Critical

1991-04-17 Publication of AP129A publication Critical patent/AP129A/en

Links

210000003527 eukaryotic cell Anatomy 0.000 title claims abstract description 10
241001430294 unidentified retrovirus Species 0.000 title abstract description 6
101710177291 Gag polyprotein Proteins 0.000 title description 19
101710125418 Major capsid protein Proteins 0.000 title description 18
108090000623 proteins and genes Proteins 0.000 claims abstract description 96
239000002243 precursor Substances 0.000 claims abstract description 93
102000004169 proteins and genes Human genes 0.000 claims abstract description 84
108020004511 Recombinant DNA Proteins 0.000 claims abstract description 29
238000000034 method Methods 0.000 claims abstract description 17
210000004027 cell Anatomy 0.000 claims description 106
239000002245 particle Substances 0.000 claims description 88
241000700605 Viruses Species 0.000 claims description 47
102000053602 DNA Human genes 0.000 claims description 27
108091026890 Coding region Proteins 0.000 claims description 23
230000001105 regulatory effect Effects 0.000 claims description 19
206010061598 Immunodeficiency Diseases 0.000 claims description 17
208000029462 Immunodeficiency disease Diseases 0.000 claims description 17
239000003636 conditioned culture medium Substances 0.000 claims description 17
230000007813 immunodeficiency Effects 0.000 claims description 17
229960005486 vaccine Drugs 0.000 claims description 17
210000004962 mammalian cell Anatomy 0.000 claims description 15
241000238631 Hexapoda Species 0.000 claims description 14
208000015181 infectious disease Diseases 0.000 claims description 14
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
241000255777 Lepidoptera Species 0.000 claims description 12
241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 10
230000003612 virological effect Effects 0.000 claims description 10
230000002163 immunogen Effects 0.000 claims description 9
241001465754 Metazoa Species 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 7
210000002966 serum Anatomy 0.000 claims description 6
108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
230000029302 virus maturation Effects 0.000 claims description 5
241000256248 Spodoptera Species 0.000 claims description 3
210000001124 body fluid Anatomy 0.000 claims description 3
108020005065 3' Flanking Region Proteins 0.000 claims description 2
108020005029 5' Flanking Region Proteins 0.000 claims description 2
101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 claims description 2
241000287828 Gallus gallus Species 0.000 claims description 2
206010025323 Lymphomas Diseases 0.000 claims description 2
101150012394 PHO5 gene Proteins 0.000 claims description 2
206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
201000000050 myeloid neoplasm Diseases 0.000 claims description 2
230000029812 viral genome replication Effects 0.000 claims description 2
210000005253 yeast cell Anatomy 0.000 claims description 2
238000012258 culturing Methods 0.000 claims 4
101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 claims 2
241000700618 Vaccinia virus Species 0.000 claims 2
238000003745 diagnosis Methods 0.000 claims 2
108010021809 Alcohol dehydrogenase Proteins 0.000 claims 1
101100480861 Caldanaerobacter subterraneus subsp. tengcongensis (strain DSM 15242 / JCM 11007 / NBRC 100824 / MB4) tdh gene Proteins 0.000 claims 1
101100447466 Candida albicans (strain WO-1) TDH1 gene Proteins 0.000 claims 1
101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 claims 1
101001000154 Schistosoma mansoni Phosphoglycerate kinase Proteins 0.000 claims 1
210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
101150088047 tdh3 gene Proteins 0.000 claims 1
210000003501 vero cell Anatomy 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 58
241000725303 Human immunodeficiency virus Species 0.000 description 37
101710205625 Capsid protein p24 Proteins 0.000 description 31
101710177166 Phosphoprotein Proteins 0.000 description 31
101710149279 Small delta antigen Proteins 0.000 description 31
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 31
102100036352 Protein disulfide-isomerase Human genes 0.000 description 27
239000012634 fragment Substances 0.000 description 24
241000701447 unidentified baculovirus Species 0.000 description 24
BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 21
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 20
239000000427 antigen Substances 0.000 description 17
108091007433 antigens Proteins 0.000 description 17
102000036639 antigens Human genes 0.000 description 17
241000713311 Simian immunodeficiency virus Species 0.000 description 16
108020004414 DNA Proteins 0.000 description 15
239000013598 vector Substances 0.000 description 15
238000003556 assay Methods 0.000 description 13
238000001262 western blot Methods 0.000 description 13
210000000170 cell membrane Anatomy 0.000 description 12
239000000047 product Substances 0.000 description 12
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
238000002474 experimental method Methods 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 10
208000030507 AIDS Diseases 0.000 description 9
230000034303 cell budding Effects 0.000 description 9
108091034117 Oligonucleotide Proteins 0.000 description 8
101710182846 Polyhedrin Proteins 0.000 description 8
108010027225 gag-pol Fusion Proteins Proteins 0.000 description 8
229920001184 polypeptide Polymers 0.000 description 8
COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 7
239000000499 gel Substances 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 6
239000004471 Glycine Substances 0.000 description 6
108091005804 Peptidases Proteins 0.000 description 6
239000004365 Protease Substances 0.000 description 6
229920004890 Triton X-100 Polymers 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000000872 buffer Substances 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
238000001493 electron microscopy Methods 0.000 description 6
239000013604 expression vector Substances 0.000 description 6
239000000284 extract Substances 0.000 description 6
238000005755 formation reaction Methods 0.000 description 6
239000012528 membrane Substances 0.000 description 6
-1 pi7 Proteins 0.000 description 6
230000008569 process Effects 0.000 description 6
238000002965 ELISA Methods 0.000 description 5
102100034349 Integrase Human genes 0.000 description 5
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
229920001213 Polysorbate 20 Polymers 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
238000010276 construction Methods 0.000 description 5
239000007771 core particle Substances 0.000 description 5
108700004026 gag Genes Proteins 0.000 description 5
101150098622 gag gene Proteins 0.000 description 5
238000002372 labelling Methods 0.000 description 5
230000007498 myristoylation Effects 0.000 description 5
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
238000012360 testing method Methods 0.000 description 5
238000001890 transfection Methods 0.000 description 5
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 4
241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 4
101710132601 Capsid protein Proteins 0.000 description 4
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 4
235000021360 Myristic acid Nutrition 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000003599 detergent Substances 0.000 description 4
238000012423 maintenance Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000008188 pellet Substances 0.000 description 4
239000000523 sample Substances 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
238000005199 ultracentrifugation Methods 0.000 description 4
241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 4
108010039627 Aprotinin Proteins 0.000 description 3
206010061818 Disease progression Diseases 0.000 description 3
101710091045 Envelope protein Proteins 0.000 description 3
108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
101710188315 Protein X Proteins 0.000 description 3
210000004102 animal cell Anatomy 0.000 description 3
229960004405 aprotinin Drugs 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
239000013599 cloning vector Substances 0.000 description 3
210000000805 cytoplasm Anatomy 0.000 description 3
239000007857 degradation product Substances 0.000 description 3
230000037433 frameshift Effects 0.000 description 3
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
238000004626 scanning electron microscopy Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000012546 transfer Methods 0.000 description 3
241001529453 unidentified herpesvirus Species 0.000 description 3
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 2
KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 2
241001203868 Autographa californica Species 0.000 description 2
241000255789 Bombyx mori Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
208000003322 Coinfection Diseases 0.000 description 2
SWDNPSMMEWRNOH-HJGDQZAQSA-N Glu-Pro-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWDNPSMMEWRNOH-HJGDQZAQSA-N 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
239000000232 Lipid Bilayer Substances 0.000 description 2
102000003792 Metallothionein Human genes 0.000 description 2
108090000157 Metallothionein Proteins 0.000 description 2
241000713862 Moloney murine sarcoma virus Species 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
241000712907 Retroviridae Species 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
NRCJWSGXMAPYQX-LPEHRKFASA-N Ser-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N)C(=O)O NRCJWSGXMAPYQX-LPEHRKFASA-N 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
241000255993 Trichoplusia ni Species 0.000 description 2
101150050575 URA3 gene Proteins 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
108020000999 Viral RNA Proteins 0.000 description 2
230000002411 adverse Effects 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
244000309464 bull Species 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
101150047047 gag-pol gene Proteins 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
244000052769 pathogen Species 0.000 description 2
108010073101 phenylalanylleucine Proteins 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
108700004029 pol Genes Proteins 0.000 description 2
101150088264 pol gene Proteins 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
108010077112 prolyl-proline Proteins 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
101150090724 3 gene Proteins 0.000 description 1
HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
241000714195 Aids-associated retrovirus Species 0.000 description 1
YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 1
VBDMWOKJZDCFJM-FXQIFTODSA-N Ala-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N VBDMWOKJZDCFJM-FXQIFTODSA-N 0.000 description 1
JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
CCUAQNUWXLYFRA-IMJSIDKUSA-N Ala-Asn Chemical compound C[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC(N)=O CCUAQNUWXLYFRA-IMJSIDKUSA-N 0.000 description 1
MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 1
YCRAFFCYWOUEOF-DLOVCJGASA-N Ala-Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 YCRAFFCYWOUEOF-DLOVCJGASA-N 0.000 description 1
IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 1
XPBVBZPVNFIHOA-UVBJJODRSA-N Ala-Trp-Val Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@H](C)N)=CNC2=C1 XPBVBZPVNFIHOA-UVBJJODRSA-N 0.000 description 1
102100027211 Albumin Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
DBKNLHKEVPZVQC-LPEHRKFASA-N Arg-Ala-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O DBKNLHKEVPZVQC-LPEHRKFASA-N 0.000 description 1
RWWPBOUMKFBHAL-FXQIFTODSA-N Arg-Asn-Cys Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(O)=O RWWPBOUMKFBHAL-FXQIFTODSA-N 0.000 description 1
HPSVTWMFWCHKFN-GARJFASQSA-N Arg-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O HPSVTWMFWCHKFN-GARJFASQSA-N 0.000 description 1
PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 1
BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
MTYLORHAQXVQOW-AVGNSLFASA-N Arg-Lys-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O MTYLORHAQXVQOW-AVGNSLFASA-N 0.000 description 1
CZUHPNLXLWMYMG-UBHSHLNASA-N Arg-Phe-Ala Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 CZUHPNLXLWMYMG-UBHSHLNASA-N 0.000 description 1
SWLOHUMCUDRTCL-ZLUOBGJFSA-N Asn-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N SWLOHUMCUDRTCL-ZLUOBGJFSA-N 0.000 description 1
BZMWJLLUAKSIMH-FXQIFTODSA-N Asn-Glu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BZMWJLLUAKSIMH-FXQIFTODSA-N 0.000 description 1
COWITDLVHMZSIW-CIUDSAMLSA-N Asn-Lys-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O COWITDLVHMZSIW-CIUDSAMLSA-N 0.000 description 1
BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 1
FYRVDDJMNISIKJ-UWVGGRQHSA-N Asn-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FYRVDDJMNISIKJ-UWVGGRQHSA-N 0.000 description 1
MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 1
XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 1
CLUMZOKVGUWUFD-CIUDSAMLSA-N Asp-Leu-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O CLUMZOKVGUWUFD-CIUDSAMLSA-N 0.000 description 1
FOXXZZGDIAQPQI-XKNYDFJKSA-N Asp-Pro-Ser-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FOXXZZGDIAQPQI-XKNYDFJKSA-N 0.000 description 1
JJQGZGOEDSSHTE-FOHZUACHSA-N Asp-Thr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JJQGZGOEDSSHTE-FOHZUACHSA-N 0.000 description 1
BYLPQJAWXJWUCJ-YDHLFZDLSA-N Asp-Tyr-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O BYLPQJAWXJWUCJ-YDHLFZDLSA-N 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
101100422644 Caenorhabditis elegans syx-5 gene Proteins 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
DZSICRGTVPDCRN-YUMQZZPRSA-N Cys-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CS)N DZSICRGTVPDCRN-YUMQZZPRSA-N 0.000 description 1
JLZCAZJGWNRXCI-XKBZYTNZSA-N Cys-Thr-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O JLZCAZJGWNRXCI-XKBZYTNZSA-N 0.000 description 1
PXEGEYISOXISDV-XIRDDKMYSA-N Cys-Trp-Lys Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CS)=CNC2=C1 PXEGEYISOXISDV-XIRDDKMYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
102100024746 Dihydrofolate reductase Human genes 0.000 description 1
241000255597 Drosophila hydei Species 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241001200922 Gagata Species 0.000 description 1
241000255896 Galleria mellonella Species 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 1
MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 1
IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
LYCDZGLXQBPNQU-WDSKDSINSA-N Glu-Gly-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CS)C(O)=O LYCDZGLXQBPNQU-WDSKDSINSA-N 0.000 description 1
IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 1
YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 description 1
YQAQQKPWFOBSMU-WDCWCFNPSA-N Glu-Thr-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O YQAQQKPWFOBSMU-WDCWCFNPSA-N 0.000 description 1
MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 1
108010033128 Glucan Endo-1,3-beta-D-Glucosidase Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 description 1
UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 1
NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 1
RJVZMGQMJOQIAX-GJZGRUSLSA-N Gly-Trp-Met Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(O)=O RJVZMGQMJOQIAX-GJZGRUSLSA-N 0.000 description 1
SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 1
RYAOJUMWLWUGNW-QMMMGPOBSA-N Gly-Val-Gly Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O RYAOJUMWLWUGNW-QMMMGPOBSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
108010010369 HIV Protease Proteins 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
241000255967 Helicoverpa zea Species 0.000 description 1
PGRPSOUCWRBWKZ-DLOVCJGASA-N His-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CN=CN1 PGRPSOUCWRBWKZ-DLOVCJGASA-N 0.000 description 1
VIJMRAIWYWRXSR-CIUDSAMLSA-N His-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 VIJMRAIWYWRXSR-CIUDSAMLSA-N 0.000 description 1
BRQKGRLDDDQWQJ-MBLNEYKQSA-N His-Thr-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O BRQKGRLDDDQWQJ-MBLNEYKQSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
241000829111 Human polyomavirus 1 Species 0.000 description 1
241001135958 Human type D retrovirus Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
CQQGCWPXDHTTNF-GUBZILKMSA-N Leu-Ala-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O CQQGCWPXDHTTNF-GUBZILKMSA-N 0.000 description 1
YKNBJXOJTURHCU-DCAQKATOSA-N Leu-Asp-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YKNBJXOJTURHCU-DCAQKATOSA-N 0.000 description 1
MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 1
WIDZHJTYKYBLSR-DCAQKATOSA-N Leu-Glu-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WIDZHJTYKYBLSR-DCAQKATOSA-N 0.000 description 1
LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 1
ZRHDPZAAWLXXIR-SRVKXCTJSA-N Leu-Lys-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O ZRHDPZAAWLXXIR-SRVKXCTJSA-N 0.000 description 1
REPBGZHJKYWFMJ-KKUMJFAQSA-N Leu-Lys-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N REPBGZHJKYWFMJ-KKUMJFAQSA-N 0.000 description 1
LHSGPCFBGJHPCY-STQMWFEESA-N Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-STQMWFEESA-N 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
CIOWSLJGLSUOME-BQBZGAKWSA-N Lys-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O CIOWSLJGLSUOME-BQBZGAKWSA-N 0.000 description 1
GCMWRRQAKQXDED-IUCAKERBSA-N Lys-Glu-Gly Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)N[C@@H](CCC([O-])=O)C(=O)NCC([O-])=O GCMWRRQAKQXDED-IUCAKERBSA-N 0.000 description 1
DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
XOQMURBBIXRRCR-SRVKXCTJSA-N Lys-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN XOQMURBBIXRRCR-SRVKXCTJSA-N 0.000 description 1
ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 description 1
WINFHLHJTRGLCV-BZSNNMDCSA-N Lys-Tyr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=C(O)C=C1 WINFHLHJTRGLCV-BZSNNMDCSA-N 0.000 description 1
IKXQOBUBZSOWDY-AVGNSLFASA-N Lys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N IKXQOBUBZSOWDY-AVGNSLFASA-N 0.000 description 1
241000255908 Manduca sexta Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
KMSMNUFBNCHMII-IHRRRGAJSA-N Met-Leu-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN KMSMNUFBNCHMII-IHRRRGAJSA-N 0.000 description 1
YYEIFXZOBZVDPH-DCAQKATOSA-N Met-Lys-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O YYEIFXZOBZVDPH-DCAQKATOSA-N 0.000 description 1
ZYTPOUNUXRBYGW-YUMQZZPRSA-N Met-Met Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CCSC ZYTPOUNUXRBYGW-YUMQZZPRSA-N 0.000 description 1
ILKCLLLOGPDNIP-RCWTZXSCSA-N Met-Met-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ILKCLLLOGPDNIP-RCWTZXSCSA-N 0.000 description 1
BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
108010002311 N-glycylglutamic acid Proteins 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
108010066427 N-valyltryptophan Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
JEGFCFLCRSJCMA-IHRRRGAJSA-N Phe-Arg-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N JEGFCFLCRSJCMA-IHRRRGAJSA-N 0.000 description 1
UUWCIPUVJJIEEP-SRVKXCTJSA-N Phe-Asn-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N UUWCIPUVJJIEEP-SRVKXCTJSA-N 0.000 description 1
WPTYDQPGBMDUBI-QWRGUYRKSA-N Phe-Gly-Asn Chemical compound N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O WPTYDQPGBMDUBI-QWRGUYRKSA-N 0.000 description 1
SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 1
241000235648 Pichia Species 0.000 description 1
VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
UUHXBJHVTVGSKM-BQBZGAKWSA-N Pro-Gly-Asn Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UUHXBJHVTVGSKM-BQBZGAKWSA-N 0.000 description 1
XQPHBAKJJJZOBX-SRVKXCTJSA-N Pro-Lys-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O XQPHBAKJJJZOBX-SRVKXCTJSA-N 0.000 description 1
LGMBKOAPPTYKLC-JYJNAYRXSA-N Pro-Phe-Arg Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(O)=O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 LGMBKOAPPTYKLC-JYJNAYRXSA-N 0.000 description 1
RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 1
LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
FUOGXAQMNJMBFG-WPRPVWTQSA-N Pro-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FUOGXAQMNJMBFG-WPRPVWTQSA-N 0.000 description 1
DGDCSVGVWWAJRS-AVGNSLFASA-N Pro-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 DGDCSVGVWWAJRS-AVGNSLFASA-N 0.000 description 1
VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical group CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 1
241001456341 Rachiplusia ou Species 0.000 description 1
101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
208000005074 Retroviridae Infections Diseases 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
241000235346 Schizosaccharomyces Species 0.000 description 1
NUEHQDHDLDXCRU-GUBZILKMSA-N Ser-Pro-Arg Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NUEHQDHDLDXCRU-GUBZILKMSA-N 0.000 description 1
NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
101150033766 Syn3 gene Proteins 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 1
IMDMLDSVUSMAEJ-HJGDQZAQSA-N Thr-Leu-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IMDMLDSVUSMAEJ-HJGDQZAQSA-N 0.000 description 1
SCSVNSNWUTYSFO-WDCWCFNPSA-N Thr-Lys-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O SCSVNSNWUTYSFO-WDCWCFNPSA-N 0.000 description 1
XNTVWRJTUIOGQO-RHYQMDGZSA-N Thr-Met-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XNTVWRJTUIOGQO-RHYQMDGZSA-N 0.000 description 1
AHERARIZBPOMNU-KATARQTJSA-N Thr-Ser-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O AHERARIZBPOMNU-KATARQTJSA-N 0.000 description 1
101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
MICFJCRQBFSKPA-UMPQAUOISA-N Trp-Met-Thr Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)=CNC2=C1 MICFJCRQBFSKPA-UMPQAUOISA-N 0.000 description 1
OJKVFAWXPGCJMF-BPUTZDHNSA-N Trp-Pro-Ser Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)N[C@@H](CO)C(=O)O OJKVFAWXPGCJMF-BPUTZDHNSA-N 0.000 description 1
ZNFPUOSTMUMUDR-JRQIVUDYSA-N Tyr-Asn-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZNFPUOSTMUMUDR-JRQIVUDYSA-N 0.000 description 1
WOAQYWUEUYMVGK-ULQDDVLXSA-N Tyr-Lys-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOAQYWUEUYMVGK-ULQDDVLXSA-N 0.000 description 1
SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 1
BIWVVOHTKDLRMP-ULQDDVLXSA-N Tyr-Pro-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BIWVVOHTKDLRMP-ULQDDVLXSA-N 0.000 description 1
SYFHQHYTNCQCCN-MELADBBJSA-N Tyr-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O SYFHQHYTNCQCCN-MELADBBJSA-N 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 1
IDKGBVZGNTYYCC-QXEWZRGKSA-N Val-Asn-Pro Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(O)=O IDKGBVZGNTYYCC-QXEWZRGKSA-N 0.000 description 1
XXWBHOWRARMUOC-NHCYSSNCSA-N Val-Lys-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XXWBHOWRARMUOC-NHCYSSNCSA-N 0.000 description 1
SJLVYVZBFDTRCG-DCAQKATOSA-N Val-Lys-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N SJLVYVZBFDTRCG-DCAQKATOSA-N 0.000 description 1
PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
LZDNBBYBDGBADK-KBPBESRZSA-N Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-KBPBESRZSA-N 0.000 description 1
STTYIMSDIYISRG-UHFFFAOYSA-N Valyl-Serine Chemical compound CC(C)C(N)C(=O)NC(CO)C(O)=O STTYIMSDIYISRG-UHFFFAOYSA-N 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
YHGREDQDBYVEOS-UHFFFAOYSA-N [acetyloxy-[2-(diacetyloxyamino)ethyl]amino] acetate Chemical compound CC(=O)ON(OC(C)=O)CCN(OC(C)=O)OC(C)=O YHGREDQDBYVEOS-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
108010013835 arginine glutamate Proteins 0.000 description 1
108010077245 asparaginyl-proline Proteins 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000012832 cell culture technique Methods 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
108010016616 cysteinylglycine Proteins 0.000 description 1
238000005034 decoration Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
108020001096 dihydrofolate reductase Proteins 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
210000001840 diploid cell Anatomy 0.000 description 1
201000010099 disease Diseases 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
108010008671 glycyl-tryptophyl-methionine Proteins 0.000 description 1
108010020688 glycylhistidine Proteins 0.000 description 1
108010050848 glycylleucine Proteins 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
210000000087 hemolymph Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
108010040030 histidinoalanine Proteins 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
108010012058 leucyltyrosine Proteins 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
108010003700 lysyl aspartic acid Proteins 0.000 description 1
108010009298 lysylglutamic acid Proteins 0.000 description 1
108010064235 lysylglycine Proteins 0.000 description 1
108010054155 lysyllysine Proteins 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
108010085203 methionylmethionine Proteins 0.000 description 1
229960000554 metrizamide Drugs 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
210000004898 n-terminal fragment Anatomy 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108010004914 prolylarginine Proteins 0.000 description 1
108010070643 prolylglutamic acid Proteins 0.000 description 1
108010029020 prolylglycine Proteins 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000164 protein isolation Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
102000055501 telomere Human genes 0.000 description 1
108091035539 telomere Proteins 0.000 description 1
108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 1
238000004627 transmission electron microscopy Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000024275 uncoating of virus Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000007502 viral entry Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
230000010464 virion assembly Effects 0.000 description 1
230000021887 virion transport Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Zoology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)
Peptides Or Proteins (AREA)

APAP/P/1989/000126A 1988-06-03 1989-05-22 Expression of retrovirus gag protein eukaryotic cells AP129A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US20227188A	1988-06-03	1988-06-03

Publications (2)

Publication Number	Publication Date
AP8900126A0 AP8900126A0 (en)	1989-07-31
AP129A true AP129A (en)	1991-04-17

Family

ID=22749175

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1989/000126A AP129A (en)	1988-06-03	1989-05-22	Expression of retrovirus gag protein eukaryotic cells

Country Status (8)

Country	Link
EP (1)	EP0345242A3 (fr)
AP (1)	AP129A (fr)
AU (2)	AU627465B2 (fr)
IL (1)	IL90381A0 (fr)
NZ (1)	NZ229297A (fr)
PT (1)	PT90731A (fr)
WO (1)	WO1991000904A1 (fr)
ZA (1)	ZA894137B (fr)

Families Citing this family (290)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2003794C (fr) *	1988-12-01	2000-02-08	Hanne R. Johansen	Expression de proteines de vih dans des cellules de drosophiles
US6174666B1 (en)	1992-03-27	2001-01-16	The United States Of America As Represented By The Department Of Health And Human Services	Method of eliminating inhibitory/instability regions from mRNA
US5786464C1 (en) *	1994-09-19	2012-04-24	Gen Hospital Corp	Overexpression of mammalian and viral proteins
US6592877B1 (en)	1995-09-01	2003-07-15	Corixa Corporation	Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en)	1995-09-01	2002-10-01	Corixa Corporation	Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en)	1995-09-01	2001-09-18	Corixa Corporation	Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6534312B1 (en)	1996-02-22	2003-03-18	Merck & Co., Inc.	Vaccines comprising synthetic genes
ES2301178T3 (es)	1996-04-05	2008-06-16	Novartis Vaccines & Diagnostic	Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular.
EP2298900A1 (fr)	1996-09-17	2011-03-23	Novartis Vaccines and Diagnostics, Inc.	Compositions et procédés de traitement de maladies intracellulaires
US6114148C1 (en) *	1996-09-20	2012-05-01	Gen Hospital Corp	High level expression of proteins
US6544523B1 (en)	1996-11-13	2003-04-08	Chiron Corporation	Mutant forms of Fas ligand and uses thereof
US6696291B2 (en)	1997-02-07	2004-02-24	Merck & Co., Inc.	Synthetic HIV gag genes
EE9900343A (et) *	1997-02-07	2000-02-15	Merck & Co., Inc.	Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
US6261562B1 (en)	1997-02-25	2001-07-17	Corixa Corporation	Compounds for immunotherapy of prostate cancer and methods for their use
DE69838584T2 (de)	1997-08-04	2008-06-26	Cell Genesys, Inc., Foster City	Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
US6914131B1 (en)	1998-10-09	2005-07-05	Chiron S.R.L.	Neisserial antigens
BR9813930A (pt)	1997-11-06	2006-12-19	Chiron Spa	antìgeno neisserial
CA2316397A1 (fr)	1997-12-24	1999-07-08	Corixa Corporation	Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
ATE446368T1 (de)	1998-01-14	2009-11-15	Novartis Vaccines & Diagnostic	Antigene aus neisseria meningitidis
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
EP1792988A3 (fr)	1998-03-18	2007-08-22	Corixa Corporation	Composés et méthodes thérapeutiques et diagnostiques du cancer du poumon
MX343752B (es)	1998-05-01	2016-11-22	Novartis Vaccines & Diagnostics Inc	Antigenos de neisseria meningitidis y composiciones que los contienen.
CN1348463A (zh)	1998-08-07	2002-05-08	华盛顿大学	免疫学单纯疱疹病毒抗原及其使用方法
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
EP1121437B1 (fr)	1998-10-15	2008-02-20	Novartis Vaccines and Diagnostics, Inc.	Genes regules dans les cellules du cancer du sein metastatique et du cancer du colon
CN100365120C (zh)	1998-12-08	2008-01-30	科里克萨有限公司	用于治疗及诊断衣原体感染的化合物和方法
DK1141331T3 (da)	1998-12-16	2009-01-05	Novartis Vaccines & Diagnostic	Human cyclinafhængig kinase (hPNQALRE)
US20020119158A1 (en)	1998-12-17	2002-08-29	Corixa Corporation	Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en)	1998-12-28	2003-06-17	Corixa Corporation	Compositions for the treatment and diagnosis of breast cancer and methods for their use
AU2221600A (en)	1998-12-31	2000-07-31	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US7625859B1 (en)	2000-02-16	2009-12-01	Oregon Health & Science University	HER-2 binding antagonists
US7393823B1 (en)	1999-01-20	2008-07-01	Oregon Health And Science University	HER-2 binding antagonists
ATE399793T1 (de)	1999-04-02	2008-07-15	Corixa Corp	Verbindungen und verfahren für therapie und diagnose von lungenkrebs
US8143386B2 (en)	1999-04-07	2012-03-27	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis antigens and their uses
NZ571167A (en)	1999-04-30	2010-05-28	Novartis Vaccines & Diagnostic	Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
GB9911683D0 (en)	1999-05-19	1999-07-21	Chiron Spa	Antigenic peptides
GB9916529D0 (en)	1999-07-14	1999-09-15	Chiron Spa	Antigenic peptides
EP1229931A4 (fr)	1999-10-07	2003-05-28	Corixa Corp	Proteines hybrides de mycobacterium tuberculosis
PT2275551E (pt)	1999-10-29	2015-06-29	Novartis Vaccines & Diagnostic	Péptidos antigénicos de neisseria
PT1232264E (pt)	1999-11-18	2009-11-26	Novartis Vaccines & Diagnostic	Gene fgf-21 humano e produtos da expressão do gene
ES2588917T3 (es)	2000-01-17	2016-11-07	Glaxosmithkline Biologicals Sa	Vacuna de VME suplementada contra meningococo
EP1854476A3 (fr)	2000-02-09	2008-05-07	Bas Medical, Inc.	Utilisation de la relaxine pour traiter des maladies associées à la vasoconstriction
SI1650221T1 (sl)	2000-02-23	2012-09-28	Glaxosmithkline Biolog Sa	Nove spojine
WO2001062893A2 (fr)	2000-02-25	2001-08-30	Corixa Corporation	Composes et methodes de diagnostic et d'immunotherapie de la tuberculose
PT2270030E (pt)	2000-02-28	2012-07-24	Novartis Vaccines & Diagnostic	Expressão heteróloga de proteínas de neisseria
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001066595A2 (fr)	2000-03-08	2001-09-13	Chiron Corporation	Gene humain fgf-23 et produits d'expression associes
AU2001255596A1 (en)	2000-04-21	2001-11-07	Corixa Corporation	Compounds and methods for treatment and diagnosis of chlamydial infection
PT1284740E (pt)	2000-05-19	2008-07-09	Corixa Corp	Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos
EP1950297A2 (fr)	2000-05-31	2008-07-30	Novartis Vaccines and Diagnostics, Inc.	Compositions et procédés de traitement de maladie néoplastique utilisant la chimiothérapie et des sensibilisateurs à rayonnement
US7700359B2 (en)	2000-06-02	2010-04-20	Novartis Vaccines And Diagnostics, Inc.	Gene products differentially expressed in cancerous cells
DE60134275D1 (de)	2000-06-15	2008-07-10	Novartis Vaccines & Diagnostic	Polynukleotide zur bestimmung von kolonkrebs
PT2133100E (pt)	2000-06-20	2012-01-11	Corixa Corp	Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
EP1319069B1 (fr)	2000-06-28	2008-05-21	Corixa Corporation	Compositions et methodes pour le traitement et le diagnostic du cancer du poumon
US7691821B2 (en)	2001-09-19	2010-04-06	University Of South Florida	Inhibition of SHIP to enhance stem cell harvest and transplantation
US20020165192A1 (en)	2000-09-19	2002-11-07	Kerr William G.	Control of NK cell function and survival by modulation of ship activity
US7939087B2 (en)	2000-10-27	2011-05-10	Novartis Vaccines And Diagnostics, Inc.	Nucleic acids and proteins from Streptococcus groups A & B
WO2002046477A2 (fr)	2000-12-07	2002-06-13	Chiron Corporation	Retrovirus endogenes regules positivement dans le cancer de la prostate
GB0107658D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Streptococcus pneumoniae
GB0107661D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
AU2002303261A1 (en)	2001-04-06	2002-10-21	Georgetown University	Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081641A2 (fr)	2001-04-06	2002-10-17	Georgetown University	Gene scc-112 et utilisations diagnostique et therapeutique de ce gene
WO2002081642A2 (fr)	2001-04-06	2002-10-17	Georgetown University	Gene brcc-3 et ses utilisations diagnostiques et therapeutiques
CA2446788A1 (fr)	2001-05-09	2002-11-14	Corixa Corporation	Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
EP1409694A4 (fr)	2001-07-05	2006-02-08	Chiron Corp	Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
AU2002320314A1 (en)	2001-07-05	2003-01-21	Chiron, Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
ATE466020T1 (de)	2001-11-09	2010-05-15	Univ Georgetown	Neue isoform des gefässendothelzell wachstumshemmers (vegi)
ES2386386T3 (es)	2001-12-12	2012-08-20	Novartis Vaccines And Diagnostics S.R.L.	Inmunización contra Chlamydia trachomatis
EP1581119B1 (fr)	2001-12-17	2013-01-30	Corixa Corporation	Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
EP1472375B1 (fr)	2002-01-08	2009-04-01	Novartis Vaccines and Diagnostics, Inc.	Produits geniques a expression differenciee dans des cellules cancereuses du sein et methodes d'utilisation associees
AU2003213118A1 (en)	2002-02-15	2003-09-09	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
CA2479118A1 (fr)	2002-03-15	2003-09-25	Wyeth Holdings Corporation	Mutants de la proteine p4 de haemophilus influenzae non typable a activite enzymatique reduite
WO2003080808A2 (fr)	2002-03-21	2003-10-02	Sagres Discovery, Inc.	Nouvelles compositions et nouveaux procedes pour le cancer
US7138512B2 (en)	2002-04-10	2006-11-21	Georgetown University	Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en)	2002-04-10	2007-07-17	Georgetown University	Gene shinc-3 and diagnostic and therapeutic uses thereof
US20030206916A1 (en)	2002-05-03	2003-11-06	Rush-Presbyterian-St. Luke's Medical Center	Immunogenic peptides
US8518694B2 (en)	2002-06-13	2013-08-27	Novartis Vaccines And Diagnostics, Inc.	Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
DE60324678D1 (de)	2002-07-18	2008-12-24	Univ Washington	N t-lymphozyten und damit identifizierte hsv-antigene
UA80447C2 (en)	2002-10-08	2007-09-25		Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2004032870A2 (fr)	2002-10-08	2004-04-22	Rinat Neuroscience Corp.	Procedes de traitement d'une douleur post-chirurgicale par administration d'un antagoniste du facteur de croissance neuronal, et compositions renfermant celui-ci
US7255860B2 (en)	2002-10-08	2007-08-14	Rinat Neuroscience Corp.	Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US7569364B2 (en)	2002-12-24	2009-08-04	Pfizer Inc.	Anti-NGF antibodies and methods using same
US9498530B2 (en)	2002-12-24	2016-11-22	Rinat Neuroscience Corp.	Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
DK1575517T3 (da)	2002-12-24	2012-05-14	Rinat Neuroscience Corp	Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
SI1589934T1 (sl)	2003-01-06	2016-02-29	Corixa Corporation Corporation Service Company	Določene aminoalkil glukozaminid fosfat spojine in njih uporaba
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
US7767387B2 (en)	2003-06-13	2010-08-03	Sagres Discovery, Inc.	Therapeutic targets in cancer
US20040170982A1 (en)	2003-02-14	2004-09-02	Morris David W.	Novel therapeutic targets in cancer
JP2007524362A (ja)	2003-02-14	2007-08-30	サイグレスディスカバリー，インコーポレイテッド	癌における治療ｇｐｃｒ標的
KR20050111598A (ko)	2003-02-19	2005-11-25	리나트 뉴로사이언스 코퍼레이션	신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
GB0308198D0 (en)	2003-04-09	2003-05-14	Chiron Srl	ADP-ribosylating bacterial toxin
US20070178066A1 (en)	2003-04-21	2007-08-02	Hall Frederick L	Pathotropic targeted gene delivery system for cancer and other disorders
EP2353389B1 (fr)	2003-04-21	2015-11-04	Epeius Biotechnologies Corporation	Compositions permettant de traiter les troubles
WO2005007673A2 (fr)	2003-07-03	2005-01-27	Rush University Medical Center	Peptides immunogenes
US7763592B1 (en)	2003-11-20	2010-07-27	University Of South Florida	SHIP-deficiency to increase megakaryocyte progenitor production
US7807646B1 (en)	2003-11-20	2010-10-05	University Of South Florida	SHIP-deficiency to increase megakaryocyte progenitor production
JP4503617B2 (ja)	2003-12-23	2010-07-14	ライナットニューロサイエンスコーポレイション	アゴニスト抗ｔｒｋＣ抗体および該抗体を用いる方法
KR101222281B1 (ko)	2004-03-29	2013-01-28	가르파마 컴퍼니 리미티드	신규 갈렉틴 9 개변체 단백질 및 그 용도
KR101637908B1 (ko)	2004-04-07	2016-07-11	리나트 뉴로사이언스 코프.	신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
WO2006019906A1 (fr)	2004-07-14	2006-02-23	The Regents Of The University Of California	Biomarqueur pour detecter de maniere precoce un cancer des ovaires
US20060024677A1 (en)	2004-07-20	2006-02-02	Morris David W	Novel therapeutic targets in cancer
AU2005290250A1 (en)	2004-07-30	2006-04-06	Rinat Neuroscience Corp.	Antibodies directed against amyloid-beta peptide and methods using same
WO2006020684A2 (fr)	2004-08-10	2006-02-23	Institute For Multiple Myeloma And Bone Cancer Research	Procedes pour reguler la differenciation et traiter le myelome multiple
ES2730275T3 (es)	2004-09-22	2019-11-11	Glaxosmithkline Biologicals Sa	Composición inmunógena para uso en vacunación contra estafilococos
JP2008530245A (ja)	2005-02-18	2008-08-07	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	尿路病原性菌株由来の抗原
EP1701165A1 (fr)	2005-03-07	2006-09-13	Johannes Dr. Coy	Utilisation thérapeutique et diagnostique de TKTL1, ses inhibiteurs et ses activateurs
CN101184504A (zh)	2005-03-31	2008-05-21	葛兰素史密丝克莱恩生物有限公司	针对衣原体感染的疫苗
CA2604844A1 (fr)	2005-04-07	2006-10-19	Novartis Vaccines And Diagnostics, Inc.	Genes associes au cancer
AU2006235276A1 (en)	2005-04-07	2006-10-19	Novartis Vaccines And Diagnostics Inc.	CACNA1E in cancer diagnosis, detection and treatment
PT2426141E (pt)	2005-04-29	2014-11-25	Glaxosmithkline Biolog Sa	Método para prevenção ou tratamento de uma infecção por m. tuberculosis
PE20061323A1 (es)	2005-04-29	2007-02-09	Rinat Neuroscience Corp	Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
RU2486204C2 (ru)	2005-07-22	2013-06-27	Уай'З Терапьютикс Ко., Лтд.	Антитела против сd26 и способы их применения
SI3045182T1 (en)	2005-11-14	2018-08-31	Teva Pharmaceuticals International Gmbh	An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
WO2007120368A2 (fr)	2006-01-09	2007-10-25	The Regents Of The University Of California	Combinaisons immunostimulatrices de tnfrsf, tlr, nlr, rhr, du récepteur purinergique et des agonistes du récepteur de la cytokine utilisées pour les vaccins et en immunothérapie anti-tumorale
US9259463B2 (en)	2006-01-16	2016-02-16	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Chlamydia vaccine
JP2009525319A (ja)	2006-02-02	2009-07-09	ライナットニューロサイエンスコーポレイション	ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
US8524454B2 (en)	2006-04-07	2013-09-03	The Research Foundation Of State University Of New York	Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
BRPI0712850A8 (pt)	2006-06-07	2018-05-02	Bioalliance Cv	anticorpos que reconhecem um epitopo contendo carboidrato em cd-43 e cea expressados em células cancerígenas e métodos de uso dos mesmos
DK2054431T3 (da)	2006-06-09	2012-01-02	Novartis Ag	Konformere af bakterielle adhæsiner
EP2586790A3 (fr)	2006-08-16	2013-08-14	Novartis AG	Immunogènes d'Escherischia coli pathogènes des voies urinaires
EP2139447A2 (fr)	2007-03-20	2010-01-06	Harold Brem	Compositions gm-csf cosméceuticales et leurs procédés d'utilisation
ES2725450T3 (es)	2007-07-02	2019-09-24	Etubics Corp	Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
JP5737944B2 (ja)	2007-12-17	2015-06-17	ファイザー・リミテッドＰｆｉｚｅｒＬｉｍｉｔｅｄ	間質性膀胱炎の治療
CN105732813A (zh)	2007-12-18	2016-07-06	生物联合公司	识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
AU2009234389B2 (en)	2008-04-10	2014-08-21	Cell Signaling Technology, Inc.	Compositions and methods for detecting EGFR mutations in cancer
WO2009150623A1 (fr)	2008-06-13	2009-12-17	Pfizer Inc	Traitement de la prostatite chronique
TWI445716B (zh)	2008-09-12	2014-07-21	Rinat Neuroscience Corp	Ｐｃｓｋ９拮抗劑類
US20110287026A1 (en)	2008-09-23	2011-11-24	President And Fellows Of Harvard College	Sirt4 and uses thereof
WO2010080985A1 (fr)	2009-01-08	2010-07-15	Dana-Farber Cancer Institute, Inc.	Compositions et procédés pour induire la différenciation du tissu adipeux brun
WO2010086828A2 (fr)	2009-02-02	2010-08-05	Rinat Neuroscience Corporation	Anticorps monoclonaux agonistes anti-trkb
WO2010100632A2 (fr)	2009-03-06	2010-09-10	Novartis Ag	Antigènes de chlamydia
WO2010118243A2 (fr)	2009-04-08	2010-10-14	Genentech, Inc.	Utilisation d'antagonistes de il-27 pour traiter le lupus
EP2419129A2 (fr)	2009-04-14	2012-02-22	Novartis AG	Compositions pour l'immunisation contre staphylococcus aureus
WO2010146511A1 (fr)	2009-06-17	2010-12-23	Pfizer Limited	Traitement d'une vessie hyperactive
CA2768343A1 (fr)	2009-07-16	2011-01-20	Novartis Ag	Immunogenes d'escherichia coli detoxifies
US8563261B2 (en)	2009-09-28	2013-10-22	The Trustees Of The University Of Pennsylvania	Method of diagnosing and treating interstitial cystitis
GB0919690D0 (en)	2009-11-10	2009-12-23	Guy S And St Thomas S Nhs Foun	compositions for immunising against staphylococcus aureus
AU2011207348A1 (en)	2010-01-21	2012-08-02	Dana-Farber Cancer Institute, Inc.	Context specific genetic screen platform to aid in gene discovery and target validation
LT2528621T (lt)	2010-01-27	2016-12-12	Glaxosmithkline Biologicals S.A.	Modifikuoti tuberkuliozės antigenai
AR080291A1 (es)	2010-02-24	2012-03-28	Rinat Neuroscience Corp	Anticuerpos antagonistas anti receptor de il-7 y procedimientos
GB201003333D0 (en)	2010-02-26	2010-04-14	Novartis Ag	Immunogenic proteins and compositions
NZ602220A (en)	2010-03-11	2014-10-31	Rinat Neuroscience Corp	Antibodies with ph dependent antigen binding
GB201005625D0 (en)	2010-04-01	2010-05-19	Novartis Ag	Immunogenic proteins and compositions
WO2011133931A1 (fr)	2010-04-22	2011-10-27	Genentech, Inc.	Utilisation d'antagonistes d'il-27 pour traiter une maladie intestinale inflammatoire
JP2013533286A (ja)	2010-07-30	2013-08-22	セントルイスユニバーシティ	疼痛を治療する方法
WO2012064743A2 (fr)	2010-11-08	2012-05-18	The Johns Hopkins University	Procédés d'amélioration de la fonction cardiaque
EP2698635A3 (fr)	2010-12-01	2014-05-28	The University Of North Carolina At Chapel Hill	Procédés et compositions pour cibler des sites de croissance néovasculaire
WO2012072769A1 (fr)	2010-12-01	2012-06-07	Novartis Ag	Epitopes rrgb de pneumocoque et combinaisons de variantes
US9267112B2 (en)	2011-05-10	2016-02-23	The Regents Of The University Of California	Adenovirus isolated from Titi Monkeys
US10221218B2 (en)	2011-05-10	2019-03-05	The Regents Of The University Of California	Adenovirus isolated from titi monkeys
JP2014527398A (ja)	2011-06-21	2014-10-16	オンコファクターコーポレイション	がんの療法および診断のための組成物および方法
US20130071375A1 (en)	2011-08-22	2013-03-21	Saint Louis University	Compositions and methods for treating inflammation
WO2013028527A1 (fr)	2011-08-23	2013-02-28	Indiana University Research And Technology Corporation	Compositions et procédés pour traiter le cancer
EP2751126B1 (fr)	2011-08-29	2018-03-07	The Regents of The University of California	Utilisation de molécules associées au hdl pour traiter et prévenir des états pro-inflammatoires
CA2848368C (fr)	2011-09-13	2023-02-14	Dana-Farber Cancer Institute, Inc.	Compositions et procedes pour induction et activite de tissu adipeux brun a l'aide de fndc5
US10378060B2 (en)	2011-10-14	2019-08-13	Dana-Farber Cancer Institute, Inc.	ZNF365/ZFP365 biomarker predictive of anti-cancer response
SG11201401699WA (en)	2011-11-11	2014-09-26	Rinat Neuroscience Corp	Antibodies specific for trop-2 and their uses
WO2013093693A1 (fr)	2011-12-22	2013-06-27	Rinat Neuroscience Corp.	Anticorps spécifiques de staphylococcus aureus et leurs utilisations
RU2014123030A (ru)	2011-12-22	2016-02-20	Ринат Ньюросайенс Корп.	Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
US8603470B1 (en)	2012-08-07	2013-12-10	National Cheng Kung University	Use of IL-20 antagonists for treating liver diseases
US9605276B2 (en)	2012-08-24	2017-03-28	Etubics Corporation	Replication defective adenovirus vector in vaccination
RU2015115956A (ru)	2012-11-09	2017-01-10	Пфайзер Инк.	Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
JP2016524590A (ja)	2013-03-14	2016-08-18	エペイウスバイオテクノロジーズコーポレイション	遺伝子療法適用のためのチミジンキナーゼ診断アッセイ
WO2014144521A1 (fr)	2013-03-15	2014-09-18	The Regents Of The University Of California	Peptide d'origine mitochondriale mots3 régule le métabolisme et la survie cellulaire
JP2016513682A (ja)	2013-03-15	2016-05-16	ダイアックスコーポレーション	抗血漿カリクレイン抗体
WO2014144844A1 (fr)	2013-03-15	2014-09-18	The Board Of Trustees Of The Leland Stanford Junior University	Petits arn dérivés d'arnt (arnts) impliqués dans la viabilité cellulaire
JP2016518126A (ja)	2013-04-19	2016-06-23	ザリージェンツオブザユニバーシティオブカリフォルニア	ローンスターウイルス
CN105189560A (zh)	2013-05-07	2015-12-23	瑞纳神经科学公司	抗胰高血糖素受体抗体和其使用方法
US10231993B2 (en)	2013-06-27	2019-03-19	University Of Washington Through Its Center For Commercialization	Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
US20160129017A1 (en)	2013-07-01	2016-05-12	The Research Foundation for the State University New York	Ship inhibition to combat obesity
US10208125B2 (en)	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
MX371455B (es)	2013-08-02	2020-01-28	Pfizer	Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
CN105814081B (zh)	2013-11-13	2021-02-02	辉瑞大药厂	肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
WO2015087187A1 (fr)	2013-12-10	2015-06-18	Rinat Neuroscience Corp.	Anticorps anti-sclérostine
WO2015109212A1 (fr)	2014-01-17	2015-07-23	Pfizer Inc.	Anticorps anti-il-2 et compositions et utilisations de ceux-ci
MX378344B (es)	2014-03-21	2025-03-10	Teva Pharmaceuticals Int Gmbh	Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
IL247942B (en)	2014-03-27	2022-09-01	Dyax Corp	Compositions and methods for drops in macular edema as a result of diabetes
EP3134546A4 (fr)	2014-04-24	2017-12-06	Dana-Farber Cancer Institute, Inc.	Suppresseur de tumeur et biomarqueurs oncogènes prédictifs de réponse à un inhibiteur de point de contrôle anti-immunitaire
WO2015168474A1 (fr)	2014-04-30	2015-11-05	President And Fellows Of Harvard College	Protéines de fusion pour le traitement du cancer et procédés associés
ES2913205T3 (es)	2014-05-13	2022-06-01	Bioatla Inc	Proteínas biológicas activas condicionalmente
WO2015195812A1 (fr)	2014-06-17	2015-12-23	The Research Foundation For The State University Of New York	Inhibition de ship pour l'induction de l'activation de cellules tueuses naturelles
WO2015200905A2 (fr)	2014-06-28	2015-12-30	Oligasis, Llc	Doubles antagonistes de pdgf/vegf
DK3186284T3 (da)	2014-08-28	2022-05-09	Bioatla Inc	Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
US10513699B2 (en)	2014-09-03	2019-12-24	Bioatla, Llc	Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
WO2016040441A1 (fr)	2014-09-09	2016-03-17	Unum Therapeutics	Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
US20170248603A1 (en)	2014-10-06	2017-08-31	Dana-Farber Cancer Institute, Inc.	Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
AU2015328163B2 (en)	2014-10-09	2020-10-15	Dana-Farber Cancer Institute, Inc.	Multiple-variable IL-2 dose regimen for treating immune disorders
TWI595006B (zh)	2014-12-09	2017-08-11	禮納特神經系統科學公司	抗ｐｄ－１抗體類和使用彼等之方法
CA2972800A1 (fr)	2015-01-02	2016-07-07	Dyax Corp.	Anticorps bispecifiques agissant a l'encontre la kallicreine plasmatique et du facteur xii
HK1248812A1 (zh)	2015-03-06	2018-10-19	Dana-Farber Cancer Institute, Inc.	预测在食管胃癌中pd-1通路抑制剂响应的pd-l2生物标记
EP3270897A4 (fr)	2015-03-20	2018-12-05	The Regents Of The University Of Michigan	Compositions immunogènes pour une utilisation en vaccination contre les bordetella
US9758575B2 (en)	2015-04-06	2017-09-12	Yung Shin Pharmaceutical Industrial Co. Ltd.	Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
HUE057285T2 (hu)	2015-04-13	2022-04-28	Pfizer	Terápiás ellenanyagok és alkalmazásaik
WO2017015334A1 (fr)	2015-07-21	2017-01-26	Saint Louis University	Compositions et méthodes pour diagnostiquer et traiter l'infertilité associée à l'endométriose
EP3325516B1 (fr)	2015-07-21	2021-12-15	Takeda Pharmaceutical Company Limited	Anticorps monoclonal inhibiteur, dirigé contre le facteur xiia
US11066481B2 (en)	2015-07-23	2021-07-20	The Regents Of The University Of California	Antibodies to coagulation factor XIa and uses thereof
EP3337827B1 (fr)	2015-08-19	2026-07-08	Pfizer Inc.	Anticorps d'inhibiteur de la voie du facteur tissulaire et leurs utilisations
EA038146B1 (ru)	2015-09-15	2021-07-13	Сколар Рок, Инк.	Антитела к про-/латентному миостатину и их применения
EP3359651A1 (fr)	2015-10-05	2018-08-15	THE UNITED STATES OF AMERICA, represented by the S	Souche de rotavirus humain g9p[6]et utilisation comme vaccin
IL258491B2 (en)	2015-10-16	2023-09-01	Univ Columbia	Preparations and methods for inhibiting antigens of a particular lineage
WO2017066561A2 (fr)	2015-10-16	2017-04-20	President And Fellows Of Harvard College	Modulation de pd-1 des lymphocytes t régulateurs pour réguler les réponses immunitaires effectrices des lymphocytes t
EP3365369A1 (fr)	2015-10-23	2018-08-29	Pfizer Inc	Anticorps anti-il-2, compositions les contenant et leurs utilisations
WO2017075037A1 (fr)	2015-10-27	2017-05-04	Scholar Rock, Inc.	Facteurs de croissance amorcés et leurs utilisations
EP3368157B1 (fr)	2015-10-29	2022-06-29	Dana-Farber Cancer Institute, Inc.	Procédés pour identifier, évaluer, prévenir et traiter des troubles métaboliques au moyen de pm20d1 et d'acides aminés n-lipidés
CN106699889A (zh)	2015-11-18	2017-05-24	礼进生物医药科技（上海）有限公司	抗pd-1抗体及其治疗用途
IL290457B2 (en)	2015-12-30	2025-02-01	Kodiak Sciences Inc	Antibodies and their conjugates
ES2904593T3 (es)	2016-01-21	2022-04-05	Pfizer	Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
JP2019512271A (ja)	2016-03-21	2019-05-16	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用
AU2017290805B2 (en)	2016-07-01	2023-11-16	Research Development Foundation	Elimination of proliferating cells from stem cell-derived grafts
CA3034643A1 (fr)	2016-09-20	2018-03-29	Ellen Weisberg	Compositions et methodes pour l'identification, l'evaluation, la prevention et le traitement de la lma au moyen de biomarqueurs usp10 et de modulateurs
WO2018080573A1 (fr)	2016-10-28	2018-05-03	Massachusetts Institute Of Technology	Plate-forme de criblage régulatrice globale crispr/cas
WO2018148246A1 (fr)	2017-02-07	2018-08-16	Massachusetts Institute Of Technology	Procédés et compositions pour circuits génétiques à guidage par arn
US11198735B2 (en)	2017-03-03	2021-12-14	Rinat Neuroscience Corp.	Anti-GITR antibodies and methods of use thereof
WO2018167621A1 (fr)	2017-03-16	2018-09-20	Pfizer Inc.	Prototrophie à la tyrosine
CA3059938A1 (fr)	2017-04-14	2018-10-18	Kodiak Sciences Inc.	Anticorps antagonistes du facteur d du complement et leurs conjugues
WO2018200620A1 (fr)	2017-04-25	2018-11-01	National Cheng Kung University	Utilisation d'antagonistes de l'il-20 pour le traitement de maladies oculaires
JP7234142B2 (ja)	2017-06-02	2023-03-07	ファイザー・インク	Ｆｌｔ３に特異的な抗体およびその使用
CN111033631B (zh)	2017-06-13	2024-03-12	波士顿基因公司	用于生成分子功能谱、对其进行可视化和分类的系统和方法
CN110997002A (zh)	2017-07-13	2020-04-10	麻省理工学院	靶向hdac2-sp3复合体以增强突触功能
WO2019016784A1 (fr)	2017-07-21	2019-01-24	Universidade De Coimbra	Anticorps anti-nucléoline
JP7801095B2 (ja)	2017-08-01	2026-01-16	エイビーセラピューティクスインコーポレイテッド	二重特異性抗体およびその使用
US11970707B2 (en)	2017-09-18	2024-04-30	Children's Hospital Medical Center	Strong insulator and uses thereof in gene delivery
CA3073984A1 (fr)	2017-09-21	2019-03-28	Eucure (Beijing) Biopharma Co., Ltd	Anticorps anti-ctla4 et utilisations associees
AU2018344859A1 (en)	2017-10-04	2020-04-30	Hesperix SA	Articles and methods directed to personalized therapy of cancer
WO2019084553A1 (fr)	2017-10-27	2019-05-02	New York University	Anticorps anti-galectine-9 et leurs utilisations
CA3084394A1 (fr)	2017-11-24	2019-05-31	Eucure (Beijing) Biopharma Co., Ltd	Anticorps anti-ox40 et leurs utilisations
MX2020008184A (es)	2018-02-01	2020-09-22	Pfizer	Receptores de antigeno quimericos dirigidos a cd70.
MX2020008183A (es)	2018-02-01	2020-09-22	Pfizer	Anticuerpos especificos para cd70 y sus usos.
EP3755342A4 (fr)	2018-02-21	2021-11-24	The University Of Montana	Composés de tréhalose de diaryle et leurs utilisations
CN112105642B (zh)	2018-02-23	2023-01-31	祐和医药科技(北京)有限公司	抗pd-1抗体及其用途
MX387358B (es)	2018-02-28	2025-03-18	Pfizer	Variantes de il-15 y usos de las mismas
EP3759125A4 (fr)	2018-02-28	2021-12-08	Dana-Farber Cancer Institute, Inc.	Méthodes de traitement du cancer à l'aide de combinaisons d'agents de blocage anti-btnl2 et points de contrôle immunitaires
WO2019169313A1 (fr)	2018-03-02	2019-09-06	The University Of Montana	Composés de tréhalose immunogènes et leurs utilisations
CA3092588A1 (fr)	2018-03-02	2019-09-06	Kodiak Sciences Inc.	Anticorps anti-il-6 et constructions de fusion et conjugues associes
MX2020010094A (es)	2018-04-06	2021-01-15	Dana Farber Cancer Inst Inc	Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
AU2019274654B2 (en)	2018-05-23	2023-07-20	Pfizer Inc.	Antibodies specific for CD3 and uses thereof
US11525010B2 (en)	2018-05-23	2022-12-13	Pfizer Inc.	Antibodies specific for GUCY2c and uses thereof
WO2020010110A1 (fr)	2018-07-03	2020-01-09	Unum Therapeutics Inc.	Récepteurs chimériques en association avec des molécules de métabolisme trans améliorant l'importation de glucose et leurs utilisations thérapeutiques
WO2020014974A1 (fr)	2018-07-20	2020-01-23	Eucure (Beijing) Biopharma Co., Ltd	Anticorps anti-cd40 et leurs utilisations
WO2020037066A1 (fr)	2018-08-14	2020-02-20	Unum Therapeutics Inc.	Récepteurs d'antigène chimériques en association avec des molécules de trans-métabolisme modulant le cycle de krebs et leurs utilisations thérapeutiques
CA3110837A1 (fr)	2018-08-28	2020-03-05	Vor Biopharma Inc.	Cellules souches hematopoietiques genetiquement modifiees et utilisations associees
CN112739718B (zh)	2018-09-12	2024-11-26	祐和医药科技(北京)有限公司	抗tnfrsf9抗体及其用途
CN112805301B (zh)	2018-10-15	2023-07-21	安立玺荣生医(香港)有限公司	粒细胞-巨噬细胞集落刺激因子的抗体及其用途
JP7469305B2 (ja)	2018-11-19	2024-04-16	バイオサイトジェンファーマシューティカルズ（ベイジン）カンパニーリミテッド	抗ｐｄ－１抗体およびその使用
TWI851634B (zh)	2018-12-21	2024-08-11	大陸商沐特圖公司	Muc18特異性抗體
CA3127103A1 (fr)	2019-01-23	2020-07-30	New York University	Anticorps specifiques de la chaine delta 1 du recepteur des lymphocytes t
CN113660956B (zh)	2019-01-28	2024-10-29	Ab诊疗公司	双特异性抗体及其用途
WO2020169022A1 (fr)	2019-02-18	2020-08-27	Beijing Biocytogen Co., Ltd	Animaux non humains génétiquement modifiés ayant un locus d'immunoglobuline humanisée
US20220289854A1 (en)	2019-04-30	2022-09-15	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
EP3972636A4 (fr)	2019-05-23	2023-08-02	The University Of Montana	Adjuvants de vaccin à base de ligands du récepteur tlr
WO2021028726A2 (fr)	2019-07-03	2021-02-18	Bostongene Corporation	Systèmes et procédés pour la préparation d'échantillons, le séquençage d'échantillons, la correction de biais de données de séquençage et le contrôle de qualité
US20240050529A1 (en)	2019-10-07	2024-02-15	University Of Virginia Patent Foundation	Modulating lymphatic vessels in neurological disease
CA3157509A1 (fr)	2019-10-10	2021-04-15	Kodiak Sciences Inc.	Procedes de traitement d'un trouble oculaire
EP4041773A1 (fr)	2019-10-11	2022-08-17	Beth Israel Deaconess Medical Center, Inc.	Anticorps anti-tn et leurs utilisations
US20230067811A1 (en)	2020-01-24	2023-03-02	University Of Virginia Patent Foundation	Modulating lymphatic vessels in neurological disease
WO2021150925A1 (fr)	2020-01-24	2021-07-29	Dana-Farber Cancer Institute, Inc.	Utilisations de biomarqueurs pour améliorer une immunothérapie
WO2021205325A1 (fr)	2020-04-08	2021-10-14	Pfizer Inc.	Anticorps anti-gucy2c et leurs utilisations
US20230181750A1 (en)	2020-05-06	2023-06-15	Crispr Therapeutics Ag	Mask peptides and masked anti-ptk7 antibodies comprising such
CN115667532A (zh)	2020-06-02	2023-01-31	百奥赛图(北京)医药科技股份有限公司	具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物
US20230235007A1 (en)	2020-06-15	2023-07-27	Ming-Che Shih	Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
MX2023000662A (es)	2020-07-17	2023-02-27	Pfizer	Anticuerpos terapeuticos y sus usos.
WO2022023972A1 (fr)	2020-07-30	2022-02-03	Pfizer Inc.	Cellules ayant des duplications de gènes et leurs utilisations
EP4343004A3 (fr)	2020-10-19	2024-09-11	Dana-Farber Cancer Institute, Inc.	Biomarqueurs germinaux de réponse clinique et de bénéfice d'une thérapie par inhibiteur de point de contrôle immunitaire
US20240024474A1 (en)	2020-11-13	2024-01-25	David Avigan	Personalized fusion cell vaccines
US20240029829A1 (en)	2020-12-04	2024-01-25	Bostongene Corporation	Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022159793A2 (fr)	2021-01-25	2022-07-28	Dana-Farber Cancer Institute, Inc.	Procédés et compositions pour identifier un cancer de la prostate neuroendocrinien
EP4330969A1 (fr)	2021-04-29	2024-03-06	BostonGene Corporation	Techniques d'apprentissage machine pour estimer une expression de cellules tumorales dans un tissu tumoral complexe
WO2022261183A2 (fr)	2021-06-08	2022-12-15	Dana-Farber Cancer Institute, Inc.	Compositions et procédés de traitement et/ou d'identification d'un agent pour le traitement de cancers intestinaux
US20240327496A1 (en)	2021-08-02	2024-10-03	Pfizer Inc.	Improved Expression Vectors and Uses Thereof
MX2024004009A (es)	2021-09-27	2024-06-19	Sotio Biotech Inc	Polipéptidos receptores quiméricos en combinación con moléculas transmetabólicas que redirigen metabolitos de glucosa fuera de la vía de la glucólisis y usos terapéuticos de estos.
CA3237201A1 (fr)	2021-11-16	2023-05-25	Sotio Biotech Inc.	Traitement de patients atteints de liposarcome myxoide/a cellules rondes
WO2023097119A2 (fr)	2021-11-29	2023-06-01	Dana-Farber Cancer Institute, Inc.	Méthodes et compositions pour moduler riok2
AU2023213817A1 (en)	2022-01-31	2024-08-01	Bostongene Corporation	Machine learning techniques for cytometry
EP4473096A1 (fr)	2022-02-02	2024-12-11	Pfizer Inc.	Prototrophie cystéinique
CA3249166A1 (fr)	2022-02-16	2023-08-24	The Johns Hopkins University	Procédés de diminution de l'alpha-synucléine pathologique à l'aide d'agents qui modulent fndc5 ou des fragments biologiquement actifs de celui-ci
US20240029884A1 (en)	2022-07-15	2024-01-25	Bostongene Corporation	Techniques for detecting homologous recombination deficiency (hrd)
US20260053924A1 (en)	2022-08-19	2026-02-26	Sotio Biotech Inc.	Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024040207A1 (fr)	2022-08-19	2024-02-22	Sotio Biotech Inc.	Cellules tueuses naturelles (nk) génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec des molécules de trans-métabolisme et leurs utilisations thérapeutiques
WO2024215987A1 (fr)	2023-04-14	2024-10-17	Sotio Biotech Inc.	CELLULES IMMUNITAIRES POUR LE TRAITEMENT DU CANCER EN COMBINAISON AVEC DES CONJUGUÉS IL-15/IL-15Rα
EP4694916A1 (fr)	2023-04-14	2026-02-18	SOTIO Biotech Inc.	Cellules immunitaires modifiées pour le traitement d'un cancer en combinaison avec des agonistes ?? du récepteur il-2/il-15
WO2025030010A1 (fr)	2023-08-01	2025-02-06	Vor Biopharma Inc.	Compositions comprenant des cellules souches hématopoïétiques génétiquement modifiées et leurs méthodes d'utilisation
WO2025034542A1 (fr)	2023-08-04	2025-02-13	Cornell University	Panel de signature génique prédisant une réponse cancéreuse à un blocage de point de contrôle immunitaire et radiothérapie
US20260120879A1 (en)	2023-10-31	2026-04-30	Bostongene Corporation	Machine learning technique for identifying ici responders and non-responders
US20250253011A1 (en)	2024-02-02	2025-08-07	Seven Bridges Genomics Inc.	Techniques for improved tumor mutational burden (tmb) determination using a population-specific genomic reference
WO2025202359A1 (fr)	2024-03-27	2025-10-02	Adcendo Aps	Anticorps anti-gpc1 et leurs utilisations
TW202543672A (zh)	2024-03-27	2025-11-16	丹麥商阿德森多私人有限公司	抗gpc1抗體及其用途
WO2025223455A1 (fr)	2024-04-24	2025-10-30	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Anticorps anti-ptk7/b7h3 et leurs utilisations
US20260217841A1 (en)	2024-12-10	2026-07-30	Absci Corporation	Antibodies specific to prolactin receptor and therapeutic uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0230222A1 (fr) *	1986-01-06	1987-07-29	F. Hoffmann-La Roche Ag	Expression du gène gag de HTLV-III

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5931799A (ja) *	1982-08-16	1984-02-20	Science & Tech Agency	Ｂ型肝炎ウイルス遺伝子を組込んだ組換えプラスミド
US4703008A (en) *	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
NZ217645A (en) *	1985-09-25	1991-11-26	Oncogen	Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
WO1988006185A1 (fr) *	1987-02-11	1988-08-25	Scripps Clinic And Research Foundation	Vecteurs retroviraux d'expression et procedes de production d'antigenes du virus d'hepatite b
IL90048A0 (en) *	1988-04-25	1989-12-15	Merck & Co Inc	Recombinant gag precursor of hiv,its preparation and its use as aids vaccine

1989
- 1989-05-22 AP APAP/P/1989/000126A patent/AP129A/en active
- 1989-05-23 IL IL90381A patent/IL90381A0/xx unknown
- 1989-05-26 NZ NZ229297A patent/NZ229297A/en unknown
- 1989-06-01 ZA ZA894137A patent/ZA894137B/xx unknown
- 1989-06-02 PT PT90731A patent/PT90731A/pt not_active Application Discontinuation
- 1989-06-02 EP EP89870082A patent/EP0345242A3/fr not_active Withdrawn
- 1989-06-30 AU AU37256/89A patent/AU627465B2/en not_active Ceased
- 1989-07-11 AU AU43206/89A patent/AU4320689A/en not_active Abandoned
- 1989-07-11 WO PCT/US1989/002415 patent/WO1991000904A1/fr not_active Ceased

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0230222A1 (fr) *	1986-01-06	1987-07-29	F. Hoffmann-La Roche Ag	Expression du gène gag de HTLV-III

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCIENCE (March 28, 1986) Vol. 231, pp. 1580-1584: *

Also Published As

Publication number	Publication date
EP0345242A2 (fr)	1989-12-06
ZA894137B (en)	1990-06-27
WO1991000904A1 (fr)	1991-01-24
NZ229297A (en)	1992-01-29
AU627465B2 (en)	1992-08-27
AP8900126A0 (en)	1989-07-31
EP0345242A3 (fr)	1990-05-30
IL90381A0 (en)	1989-12-15
PT90731A (pt)	1989-12-29
AU3725689A (en)	1991-01-03
AU4320689A (en)	1991-02-06

Publication	Publication Date	Title
AU627465B2 (en)	1992-08-27	Expression of retrovirus gag protein in eukaryotic cells
US5643756A (en)	1997-07-01	Fusion glycoproteins
US5580773A (en)	1996-12-03	Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
AU727107B2 (en)	2000-11-30	Hiv envelope polypeptides and vaccine
Wagner et al.	1992	Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine
US6043081A (en)	2000-03-28	Expression vectors encoding recombinant proteins comprising a VPR/VPX virion incorporation domain for targeting into HIV-1 or HIV-2 virions
DE68918867T2 (de)	1995-02-16	Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
Luo et al.	1990	Expression of gag precursor protein and secretion of virus-like gag particles of HIV-2 from recombinant baculovirus-infected insect cells
PL161165B1 (pl)	1993-05-31	Sposób wytwarzania bialek wirusa AIDS PL
EP0546787A2 (fr)	1993-06-16	Expression d'immunogènes spécifiques utilisant des antigènes viraux
WO1994028929A1 (fr)	1994-12-22	Polypeptides d'enveloppe du vih
GB2181435A (en)	1987-04-23	Vaccines and immunoassays for acquired immune deficiency syndrome
IL102092A (en)	1996-11-14	Use of recombinant hiv envelope protein in medicament for treating hiv and therapeutic composition containing the agglomerated protein
EP0577894B1 (fr)	1998-01-07	Conception, construction et expression de protéines chimériques pour le développement de vaccins et de réactifs diagnostiques
JPH01500161A (ja)	1989-01-26	Ａｉｄｓの原因ウィルスの糖蛋白質、該糖蛋白質の製造方法及びワクチン
CA2155017C (fr)	2009-06-09	Fonction proteinique vpr et activite de celle-ci
CA2190972A1 (fr)	1995-11-30	Compositions de proteines transactivatrices du virus d'immunodeficience humaine
JP5290576B2 (ja)	2013-09-18	修飾されたｈｉｖ−１エンベロープタンパク質
JPH0349686A (ja)	1991-03-04	レトロウイルスｇａｇ蛋白の真核生物細胞における発現
JP2002513381A (ja)	2002-05-08	ＨＴＬＶ―Ｉ感染およびＨＴＬＶ―ＩＩ感染を予防するためのｅｎｖ―糖タンパク質ワクチン
JP3085704B2 (ja)	2000-09-11	ドロソフィラ細胞におけるｈｉｖ蛋白の発現
US6270959B1 (en)	2001-08-07	Human T-cell lymphotropic virus type II envelope protein and human monoclonal antibodies specific therefor
WO1995032000A1 (fr)	1995-11-30	Immunogenes de polyproteines de vih
Halsey	2006	Construction and characterization of chimaeric human immunodefiency virus type 1 subtype C Gag virus-like particles
LV10497B (en)	1995-10-20	A method for obtaining a vaccine comprising polypeptides derived from the HIV-1 virus envelope gene